Northland Capmk Has Positive Outlook of TLSI FY2026 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Investment analysts at Northland Capmk upped their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a research note issued on Tuesday, November 26th. Northland Capmk analyst C. Byrnes now forecasts that the company will post earnings per share of ($0.60) for the year, up from their previous forecast of ($0.75). Northland Capmk has a “Strong-Buy” rating on the stock. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share.

Several other equities analysts have also recently weighed in on TLSI. Canaccord Genuity Group cut their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Northland Securities began coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price target for the company. Oppenheimer began coverage on TriSalus Life Sciences in a report on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price for the company. Finally, Roth Mkm began coverage on TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price for the company. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus target price of $12.08.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $4.25 on Thursday. The stock has a market capitalization of $129.58 million, a PE ratio of -1.71 and a beta of 0.49. The business has a 50 day simple moving average of $4.23 and a two-hundred day simple moving average of $5.48. TriSalus Life Sciences has a 1-year low of $3.61 and a 1-year high of $10.42.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the business. Duquesne Family Office LLC lifted its stake in shares of TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. Highbridge Capital Management LLC bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $1,184,000. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares during the last quarter. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $240,000. Finally, MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $184,000. 2.58% of the stock is owned by institutional investors.

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela purchased 7,520 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $5.20 per share, with a total value of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. The trade was a 2.03 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders purchased 19,560 shares of company stock worth $95,190. 32.80% of the stock is currently owned by company insiders.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.